Skip to main content
Premium Trial:

Request an Annual Quote

Mark Stevenson, Edward Sztukowski

Premium
Applied Biosystems named Mark Stevenson its president this week, replacing Cathy Burzik who abruptly left the company in October 2006.
 
Stevenson also was named chief operating officer of the company and a senior vice president of Applera, the parent company of ABI. Stevenson, who joined ABI in 1998, had been executive vice president of ABI since July. Prior to that, he was president of the Molecular and Cell Division.
 
The appointment “completes the Applied Biosystems management transition that began more than a year ago,” said Tony White, chairman, president, and CEO of Applera, who had been acting as ABI’s president since Burzik’s departure.
 
Burzik left ABI suddenly to become CEO of Kinetic Concepts, a medical device company based in San Antonio, Texas.
 

 
Edward Sztukowski has joined BioTrove as senior vice president and chief business officer, the company said this week. His responsibilities include continuing to grow the RapidFire technology platform for mass spectrometry and OpenArray platform, and managing the business operation development for the company’s molecular diagnostics business.
 
Sztukowski was previously senior vice president and business area manager at bioMerieux. Prior to that, he was president of Remel, a manufacturer and distributor of microbiology products. He also held various positions at Abbott Laboratories Diagnostic Division.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.